Latest Supply Chains News

KTEK Aerosystems has restarted deliveries under its main production program and is targeting 150 complete airframe sets per month. But the recovery is entering its most demanding phase, with A$2.31 million of quarterly operating cash outflow and only 1.1 quarters of funding under the ASX measure.

Talga has begun commercial deliveries of Swedish-made Talnode-C to Nyobolt, marking a shift from customer qualification to ongoing supply. The ASX-listed battery materials developer also advanced a 2,000-tonne-per-year Japanese offtake pathway, but ended September with A$10.8 million in cash after A$7.6 million of operating and investing outflows.

Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.

Avenira has advanced the Wonarah phosphate project towards planned pre-strip work in late 2026 and a first direct shipping ore shipment in the first half of 2027, while securing access to up to A$85 million in post-quarter-end Hebang debt facilities. The timetable remains conditional on approvals, product qualification, pricing, logistics and funding execution.

Arcadia Minerals says financing and offtake negotiations for its construction-ready Swanson tantalum project continued to advance as reported tantalum prices reached US$243.50/lb. The company is also preparing drill targets at its TVC polymetallic project, but both development pathways remain dependent on funding and definitive agreements.

NOVONIX ended the September quarter with US$33.652 million in cash after burning US$9.765 million in operations and repaying US$7 million of Yorkville debt. Its amended PowerCo framework also removes previous volume, pricing and delivery commitments, leaving customer qualification and future funding as the company’s central tests.

Element 25 has reshaped the commercial and funding framework for its planned Louisiana HPMSM facility, retaining a US$166 million U.S. Department of Energy grant while ending its existing GM agreements. Revised Stellantis arrangements are agreed in principle but still require definitive documents, leaving the project’s replacement financing plan central to the next phase.

Wide Open Agriculture has completed the major physical steps in exiting its German manufacturing facility and is now testing four prospective Asian production partners. The transition could lower fixed costs, but commercial supply still depends on technical trials, partner selection and a definitive agreement.

OncoSil Medical enters FY27 with FDA approval for its cancer device, rising quarterly revenue and fresh institutional funding, but its U.S. opportunity still depends on reimbursement and a tightly controlled initial rollout. Cash rose to A$8.7 million after the capital raise, while operating cash use remained substantial.

Astron has cleared a major financing hurdle for its Donald Project, with government-backed lenders conditionally approving up to A$180 million toward a proposed A$200 million Phase 1 debt facility. The project still needs commercial lender commitments, joint venture approval and a final investment decision targeted for Q4 2026.

Aurora Labs has moved another step from propulsion development toward commercial production, securing AS9100D certification and its first US engine order while customer enquiries expand. But with only A$1.148 million in cash at quarter-end and 1.5 quarters of funding estimated, the A$6 million raise is central to the next phase.

The Calmer Co. posted record Q1 FY27 revenue of A$2.44 million, powered by a sharp lift in US wholesale orders and continued Coles and Woolworths growth. But with A$953,000 in cash against quarterly operating outflows of A$755,000, the kava company remains dependent on further funding and sustained sales momentum.